Pharma manufacturing news in brief
September 6, 2011Manufacturing and Production pharma manufacturing news
USP expands operations in India, DSM gets green light for Chinese anti-infective joint venture, plus there are updates from CMC …
Afinitor expands European licence
September 5, 2011Sales and Marketing Afinitor, Novartis, Pancreatic cancer
Novartis’ Afinitor has made further strides in the EU with an approval for use in patients with advanced pancreatic neuroendocrine …
NICE rejects three bowel cancer drugs
September 5, 2011Sales and Marketing Erbitux, NICE, Vectibix, avastin, colorectal cancer
NICE says three treatments – Roche’s Avastin, Merck KgAa’s Erbitux and Amgen’s Vectibix – are all not cost effective in …
Boehringer-Lilly won’t launch Trajenta in Germany
September 5, 2011Sales and Marketing Drug pricing, Germany, Tradjenta, Trajenta, price cuts
Boehringer Ingelheim and Lilly have decided not to launch their new diabetes drug Trajenta in Germany and say the country’s …
Crestor fails head-to-head test against Lipitor
September 2, 2011Sales and Marketing Crestor, Lipitor
AstraZeneca’s cholesterol drug Crestor has failed to show it can stop artery disease better than Pfizer’s Lipitor. The new study …
Philippines pricing controls: Pfizer ‘considered taking drugs off the market’
September 2, 2011Sales and Marketing Drug pricing, Philippines, price cuts
Pfizer considered withdrawing some of its products from the Philippines rather than face planned pricing controls, according to a US …
Zonegran study could pave way for paediatric licence
September 2, 2011Research and Development, Sales and Marketing Eisai, Zonegran, epilepsy, research and development news
Eisai’s epilepsy drug Zonegran has been found more effective than placebo in children with the neurological condition who have seizures. …
Robert Yates appointed president of Millipore
September 2, 2011Sales and Marketing appointment, sales and marketing
Merck KGaA has appointed diagnostics expert Robert Yates to the newly-created role of president at Millipore, the company it acquired …
Digital Pharma: Mobile marketing
September 1, 2011Medical Communications Digital Pharma blog, iphone, mobile, smart devices
“This, is not a phone,” said Mark Blayney Stuart holding up his BlackBerry. “It’s a very powerful computer that happens …
Ex-Pfizer employees set up new business at Sandwich
September 1, 2011Research and Development Pfizer, Sandwich, The Research Network, research and development news
Seven former Pfizer employees have set up a new business in Sandwich that will provide outsourcing services for the pharma …
Stem cell trial for stroke is safe
September 1, 2011Research and Development ReNeuron, Stem cells, stroke
A pioneering stem cell treatment for patients who have suffered a stroke has been ruled safe, and can continue to …
Rich Baptista joins Synergy Vision
September 1, 2011Medical Communications London, Quintiles, agency, appointment, chiltern, comms, communications, creativity, digital, excellence, innovation, leader, leadership, marketing, med, medical, medical communcations, success
London-based medical communications agency Synergy Vision has appointed Rich Baptista as strategic alliance director with a brief to focus on …
Tarceva approval for first-line use in EGFR lung cancer
September 1, 2011Sales and Marketing NSCLC, Roche, Tarceva
Tarceva has been granted final European approval for patients with a genetically distinct type of non-small cell lung cancer (NSCLC). …
Shire’s Firazyr gains US approval after initial setback
September 1, 2011Sales and Marketing FDA, Firazyr, Shire
After three years of waiting Shire’s Firazyr has been approved by the FDA for sudden attacks of swelling. The US …
Merck acquires cell imaging instrument maker Amnis
September 1, 2011Research and Development Merck KGaA, Millipore
EMD Millipore, the Massachussetts-based life sciences arm of Merck KGaA, has bought US cell imaging instrument maker Amnis Corporation for …
Boehringer expands afatinib breast cancer trials
August 31, 2011Research and Development Boehringer, afatinib
Boehringer Ingelheim has begun two new phase II trials of its investigational cancer drug afatinib. The studies will cover afatinib’s …
FDA wants more information on Novartis arthritis drug
August 31, 2011Sales and Marketing FDA, Ilaris, Novarits, canakinumab
The FDA has asked Novartis for more information on its gouty arthritis drug canakinumab. The regulator’s request came in a …
Pradaxa and Eliquis gain trial boost over warfarin
August 31, 2011Sales and Marketing Eliquis, Pradaxa, Xarelto, apixaban
A pair of new blood thinners are superior to warfarin when it comes to reducing the risk of stroke in …
Nurofen Plus recall expanded
August 31, 2011Sales and Marketing MHRA, Nurofen, recalls
Last week’s recall of Reckitt Benckiser’s painkiller product Nurofen Plus has been expanded after two additional cases emerged where powerful …
FDA approves Pfizer’s lung cancer drug Xalkori
August 30, 2011Sales and Marketing FDA, Pfizer, Xalkori, crizotinib
Pfizer’s lung cancer drug Xalkori has been approved by the FDA, a month ahead of schedule. Xalkori (crizotinib) is now …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
